Buy Rating on PROCEPT BioRobotics: Innovative BPH Solutions and Prostate Cancer Potential Drive Growth Outlook

William Blair analyst Brandon Vazquez has maintained their bullish stance on PRCT stock, giving a Buy rating on May 16.

Brandon Vazquez has given his Buy rating due to a combination of factors related to PROCEPT BioRobotics’ innovative solutions in the BPH market and potential in the prostate cancer segment. The company’s Aquablation technology is highlighted as a reliable and efficient treatment option, offering consistent outcomes and operational efficiencies in the operating room. This positions the therapy well for growth, especially considering the discussions around common concerns such as bleeding, prostate sizes, and reimbursement.
Furthermore, the anticipation of forthcoming data on prostate cancer treatments adds to the positive outlook. The mechanism of action and recent clinical publications suggest significant market opportunities, with the potential for early benefits and long-term adoption catalysts. With the stock trading at 7.5 times the 2026 sales estimate, Vazquez maintains an Outperform rating, viewing the company as having a strong growth trajectory.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRCT in relation to earlier this year.